The authors also transduced the Jurkat T-ALL cell line with a doxycycline-inducible CRISPR/Cas9 system targeting the enhancer mutation and injected these engineered cells into immunocompromised mice to evaluate the effects of the LMO1 enhancer mutation in vivo. This evidence concerns the gene LMO1 and acute lymphoblastic leukemia.